Tiotropium for adults with inadequately controlled persistent asthma

Annals of Pharmacotherapy

Volumn 47, Issue 1, 2013, Pages 117-123

  Adams, Katie S ^a   Lowe, Denise K ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE; NITRIC OXIDE; SALMETEROL; TIOTROPIUM BROMIDE;

AIRWAY RESISTANCE; ARTICLE; ASTHMA; CONTROLLED PERSISTENT ASTHMA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG VOLUME; METERED DOSE INHALER; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TOTAL LUNG CAPACITY;

ADMINISTRATION, INHALATION; ADULT; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; GLUCOCORTICOIDS; HUMANS; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; SCOPOLAMINE DERIVATIVES;

EID: 84872977876     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R502     Document Type: Article

References (28)

1. Akinbami LJ, Moorman JE, Liu X. Asthma prevalence, health care use, and mortality: United States, 2005-2009. National Health Statistics Report 2011, 32. www.cdc.gov/nchs/data/nhsr/nhsr032.pdf (accessed 2012 Jun 12).
2. Fanta CH. Asthma. N Engl J Med 2009;360:1002-14.
3. National Asthma Education and Prevention Program. Expert panel report III: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. NIH publication no. 08- 4051. www.nhlbi.nih.gov/guidelines/asthma/ (accessed 2012 Jun 12).
4. Fardon TC, Lee DKC, Haggart K, et al. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med 2004;170:960-6.
5. Van Staa TP, Leukfkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001;16:581-8.
6. Slatore CG, Bryson CL, Au DH. The association of inhaled cortico- steroid use with serum glucose concentration in a large cohort. Am J Med 2009;122:472-8.
7. Faul JL, Wilson SR, Chu JW, Canfield J, Kuschner WG. The effect of an inhaled corticosteroid on glucose control in type 2 diabetics. Clin Med Res 2009;7:14-20.
8. Casale TB, Eucklund P. Characterization of muscarinic receptor subtypes on human peripheral lung. J Appl Physiol 1988;65:594-600.
9. Barnes PJ. Muscarinic receptor subtypes in airways. Life Sci 1993;52:521-527.
10. Ohta S, Oda N, Yoke T, et al. Effect of tiotropium bromide on airway in- flammation and remodeling in a mouse model of asthma. Clin Exp Aller- gy 2010;40:1266-75.
11. Buels KS, Jacoby DB, Fryer AD. Non-bronchodilating mechanisms of tiotropium prevent airway hyperreactivity in a guinea-pig model of aller- gic asthma. Br J Pharmacol 2012;165:1501-14.
12. Westby M, Benson M, Gibson P. Anticholinergic agents for chronic asth- ma in adults. Cochran Database Syst Rev 2004;3:CD003269.
13. Product information. Spiriva (tiotropium). Ridgefield, CT: Boehringer Ingleheim Pharmaceuticals, Inc., March 2012.
14. Magnussen H, Bugnas B, van Noord J, Schmidt P, Gerken F, Kesten S. Improvements with tiotropium in COPD patients with concomitant asth- ma. Respir Med 2008;102:50-6.
15. Iwamoto H, Yokoyama A, Shiota N, et al. Tiotropium bromide is effec- tive for severe asthma with noneosinophilic phenotype. Eur Respir J 2008; 31:1379-1380.
16. Park HW, Yang MS, Park CS, et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict re- sponse. Allergy 2009;64:778-83.
17. Kapoor AS, Olsen S, O'Hara C, Puttagunta L. The efficacy of tiotropium as a steroid-sparing agent in severe asthma. Can Respir J 2009;16:99-101.
18. Fardon T, Haggart K, Lee DKC, Lipworth BJ. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respir Med 2007; 101:1218-1228.
19. Peters S P, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010;363: 1715-1726.
20. Juniper EF, O'Bryne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902-7.
21. Revicki DA, Leidy NK, Brennan-Diemer F, Sorensen S, Togias A. Inte- grating patient preferences into health outcomes assessment. Chest 1998; 114:998-1007.
22. Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999;14:32-38.
23. Bateman ED, Kornmann O, Schmidt P, et al. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg pa- tients with asthma. J Allergy Clin Immunol 2011;128:315-322.
24. Kerstjens HAM, Disse B, Schroder-Babo W, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011;128:308-314.
25. Kerstjens HAM, Engle M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012;367: 1198-1207.
26. Hochrainer D, Hölz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist Inhaler and pressurized metered dose inhalers. J Aerosol Med 2005; 18:273-282.
27. Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared with deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med 2005;18:264-272.
28. Bel EH. Tiotropium for asthma-promise and caution. N Engl J Med 2012;367:1257-1259.